Recordati granted marketing approval in EU for Cystadrops

Italian drugmaker Recordati (RECI: MI) has been granted marketing authorization by the European Medicines Agency for its orphan medicinal product Cystadrops (mercaptamine).

Cystadrops is an eye-drop solution designed to treat corneal cystine crystal deposits in adults and children over the age of two with cystinosis.

Cystinosis is a rare congenital lysosomal storage disorder recognized as a severe life threatening condition. Without effective treatment, cystine crystals accumulate in the cornea and can cause severe ophthalmic consequences, including blindness.